By Turna Ray

Myriad Genetics' recent investments to bolster the visibility of its molecular diagnostics products beyond its flagship BRACAnalysis test appear to be paying off.

For the three months ended Sept. 30, the first quarter of the company's 2012 fiscal year, revenues for Myriad's Colaris and Colaris AP tests for gauging the risk of hereditary colorectal cancer increased 35 percent to $9.6 million, outpacing the company's overall revenue growth of 20 percent to $111 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.